ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

IMMP Immutep Ltd

2.98
0.11 (3.83%)
May 31 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Immutep Ltd IMMP NASDAQ Depository Receipt
  Price Change Price Change % Share Price Last Trade
0.11 3.83% 2.98 23:00:10
Open Price Low Price High Price Close Price Previous Close
2.93 2.87 3.05 2.98 2.87
more quote information »

Recent News

Date Time Source Heading
6/02/202419:38GLOBEImmutep Announces Clinical Collaboration with MSD to..
5/15/202407:00GLOBEImmutep Presents Data from Safety Lead-in Phase of AIPAC-003..
5/02/202407:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
4/29/202407:00GLOBEImmutep Quarterly Activities Report Q3 FY24
4/24/202407:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
4/18/202407:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
4/17/202407:00GLOBEImmutep Receives Positive Feedback from the Spanish..
3/05/202407:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
1/30/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/30/202407:00GLOBEImmutep Quarterly Activities Report Q2 FY24
1/04/202407:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
12/21/202307:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
12/21/202305:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/07/202307:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
11/22/202307:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
11/09/202307:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
11/06/202307:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
11/03/202311:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
11/03/202305:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/02/202307:00GLOBEImmutep to Participate in November Investor Events
10/31/202307:00GLOBEImmutep Quarterly Activities Report Q1 FY24
10/25/202307:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
10/25/202305:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/24/202307:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
10/24/202305:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/23/202307:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
10/16/202307:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
10/03/202307:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
9/21/202307:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
9/05/202308:00GLOBEImmutep to Participate in September Investor Conferences
8/01/202307:00GLOBEImmutep Receives Positive Scientific Advice from European..
7/31/202307:00GLOBEImmutep to Present Overall Survival Data in 1st Line..
7/28/202307:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
7/28/202305:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
6/27/202307:00GLOBEImmutep Secures Third United States Patent for Eftilagimod..
6/20/202307:00GLOBEImmutep Granted United States Patent for IMP761, a..
6/07/202307:00GLOBEImmutep to Participate at the Jefferies Healthcare..
6/05/202307:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..